XPro1595

DB16454InvestigationalProtein Based Therapies

XPro1595 is an investigational dominant-negative protein that neutralizes soluble TNF.

Mechanism: XPro1595 is a PEG-ylated human TNF variant lacking TNF receptor-binding ability. It forms inactive heterotrimers with native solTNF, preventing them from binding to TNF receptors. Studies show that this compound is neuroprotective through its anti-inflammatory effects.
Curator reviewed
Also known as: HOMOSAPIENS TUMOR NECROSIS FACTOR,SOLUBLE FORM (V1>M, R31>C, C69>V, Y87>H, C101>A, A145>R), MONOMER, PEGYLATED ON CYSTEINE 31 : S-((3RS)-(2-((3-(.OMEGA.-METHOXYPOLY(OXYETHANE-1,2-DIYL))PROPYL)CARBAMOYL)ETHYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINYL · NeuLiv · PEGIPANERMIN · Quellor · SOLUBLE TUMOR NECROSIS FACTOR (1-METHIONINE,31-CYSTEINE,69-VALINE,87-HISTIDINE,101-ALANINE,145-ARGININE) (HUMAN CONSTRUCT XPRO1595), 31-THIOETHER WITH .ALPHA.-(3-((3-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOPROPYL)AMINO)PROPYL)-.OMEGA.-METHOXYPOLY(OXY-
Code names: DN-TNF · INB03 · XENP345 · XPro1595

Resolves to

Compound

Targets

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with XPro1595, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.